Oxymetazoline: Difference between revisions

Oxymetazoline
	Adult Indications & Dosage
	Pediatric Indications & Dosage
	Contraindications
	Warnings & Precautions
	Adverse Reactions
	Drug Interactions
	Use in Specific Populations
	Administration & Monitoring
	Overdosage
	Pharmacology
	Clinical Studies
	How Supplied
	Images
	Patient Counseling Information
	Precautions with Alcohol
	Brand Names
	Look-Alike Names

← Older edit

VisualWikitext

Latest revision as of 19:28, 23 December 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Deepika Beereddy, MBBS [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Oxymetazoline is a nasal decongestant, opthalmologic agent that is FDA approved for the treatment of nasal congestion, ocular irritation in conjunctivitis. Common adverse reactions include headache, insomnia, feeling nervous, rebound nasal congestion, dry nasal mucosa , nasal stinging/burning, sneezing.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

temporarily relieves nasal congestion due to:

common cold
hay fever
upper respiratory allergies
temporarily relieves sinus congestion and pressure
shrinks swollen nasal membranes so you can breathe more freely

Conjunctivitis, Ocular irritation

Dosing Information

For CONJUNCTIVITIS, the usual adult dose of oxymetazoline for adults and children 6 years old or greater is 1 to 2 drops of 0.025% ophthalmic solution instilled into the affected eye(s) every 6 hours.
Contact lens wear during ophthalmic use is not recommended

Nasal congestion

Dosing Information

For RHINITIS, the usual intranasal dose of oxymetazoline in adults and children 6 years old or greater is 2 to 3 drops or sprays of 0.05% solution in each nostril twice a day for up to 3 days

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Oxymetazoline in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Oxymetazoline in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Conjunctivitis, Ocular irritation

Nasal congestion

Dosing Information

For RHINITIS, the usual dose of oxymetazoline in children 2 to 5 years old is 2 to 3 drops of a 0.025% solution in each nostril twice a day for up to 3 days. Drops are preferred to spray dosage forms since dosage can be more easily controlled with the former.
Use should be limited to less than 5 days to minimize occurrence of rebound congestion.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Oxymetazoline in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Oxymetazoline in pediatric patients.

Contraindications

There is limited information regarding Oxymetazoline Contraindications in the drug label.

Warnings

Ask a doctor before use if you have

heart disease
high blood pressure
diabetes
thyroid disease
trouble urinating due to an enlarged prostate gland

When using this product

do not use more than directed
do not use for more than 3 days. Use only as directed. Frequent or prolonged use may cause nasal congestion to recur or worsen.
temporary discomfort such as burning, stinging, sneezing or an increase in nasal discharge may occur
use of this container by more than one person may spread infection

Stop use and ask a doctor if

symptoms persist

If pregnant or breast-feeding,

ask a health professional before use.

Keep out of reach of children.

If swallowed, get medical help or contact a Poison Control Center right away. (1-800-222-1222)

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Oxymetazoline in the drug label.

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Oxymetazoline in the drug label.

Drug Interactions

There is limited information regarding Oxymetazoline Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

Pregnancy Category

Pregnancy Category (AUS):

Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Oxymetazoline in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Oxymetazoline during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Oxymetazoline with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Oxymetazoline with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Oxymetazoline with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Oxymetazoline with respect to specific gender populations.

Race

There is no FDA guidance on the use of Oxymetazoline with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Oxymetazoline in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Oxymetazoline in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Oxymetazoline in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Oxymetazoline in patients who are immunocompromised.

Administration and Monitoring

Administration

Intravenous

Monitoring

There is limited information regarding Monitoring of Oxymetazoline in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Oxymetazoline in the drug label.

Overdosage

There is limited information regarding Chronic Overdose of Oxymetazoline in the drug label.

Pharmacology

Mechanism of Action

Structure

File:Oxymetazoline01.png

This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Oxymetazoline in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Oxymetazoline in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Oxymetazoline in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Oxymetazoline in the drug label.

How Supplied

Storage

store at 20°-25°C (68°-77°F)
retain carton for future reference on full labeling

Images

Drug Images

{{#ask: Page Name::Oxymetazoline |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Oxymetazoline |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

adults and children 6 to under 12 years of age (with adult supervision): 2 or 3 sprays in each nostril not more often than every 10 to 12 hours. Do not exceed 2 doses in any 24-hour period.
children under 6 years of age: ask a doctor

To spray, squeeze bottle quickly and firmly. Do not tilt head backward while spraying. Wipe nozzle clean after use. Replace cap tightly to maintain child resistance.

Precautions with Alcohol

Alcohol-Oxymetazoline interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Afrin, 4-Way Long Lasting, Neo-Synephrine 12 Hour, Vicks Sinex 12 Hour, Visine L.R., Nasacon, Sinarest Nasal, Duramist Plus.

Look-Alike Drug Names

A® — B®^[1]

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

↑ "http://www.ismp.org". External link in |title= (help)

{{#subobject:

 |Page Name=Oxymetazoline
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Oxymetazoline
 |Label Name=Oxymetazoline11.png

}}

{{#subobject:

 |Label Page=Oxymetazoline
 |Label Name=Oxymetazoline11.png

}}

[www.ismp.org-1] "http://www.ismp.org". External link in |title= (help)

[1]

@@ Line 1: / Line 1: @@
 {{DrugProjectFormSinglePage
-|authorTag=<!--Overview-->
+|authorTag={{DB}}
+|genericName=Oxymetazoline
 |aOrAn=a
-|drugClass=
+|drugClass=nasal decongestant, opthalmologic agent
-|indicationType=
+|indicationType=treatment
-|indication=
+|indication=nasal congestion, ocular irritation in [[conjunctivitis]]
-|hasBlackBoxWarning=Yes
+|adverseReactions=[[headache]], [[insomnia]], feeling nervous, rebound nasal congestion, dry nasal mucosa , [[nasal stinging]]/burning, [[sneezing]]
-|adverseReactions=<!--Black Box Warning-->
 |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
 |blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
@@ Line 15: / Line 15: @@
 <!--FDA-Labeled Indications and Dosage (Adult)-->
-|fdaLIADAdult======Condition1=====
+|fdaLIADAdult=*temporarily relieves nasal congestion due to:
+:*common cold
+:*[[hay fever]]
+:*[[upper respiratory allergies]]
+:*temporarily relieves [[sinus congestion]] and pressure
+:*shrinks swollen nasal membranes so you can breathe more freely
-* Dosing Information
+=====Conjunctivitis, Ocular irritation=====
-:* Dosage
-=====Condition2=====
 * Dosing Information
-:* Dosage
+:*For [[CONJUNCTIVITIS]], the usual adult dose of oxymetazoline for adults and children 6 years old or greater is 1 to 2 drops of 0.025% ophthalmic solution instilled into the affected eye(s) every 6 hours.
+:* Contact lens wear during ophthalmic use is not recommended
-=====Condition3=====
+=====Nasal congestion=====
 * Dosing Information
-:* Dosage
+:* For [[RHINITIS]], the usual intranasal dose of oxymetazoline in adults and children 6 years old or greater is 2 to 3 drops or sprays of 0.05% solution in each nostril twice a day for up to 3 days
-=====Condition4=====
-* Dosing Information
-:* Dosage
 <!--Off-Label Use and Dosage (Adult)-->
 <!--Guideline-Supported Use (Adult)-->
-|offLabelAdultGuideSupport======Condition1=====
+|offLabelAdultGuideSupport=* There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
-* Developed by:
-* Class of Recommendation:
-* Strength of Evidence:
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 <!--Non–Guideline-Supported Use (Adult)-->
-|offLabelAdultNoGuideSupport======Condition1=====
+|offLabelAdultNoGuideSupport=* There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 <!--Pediatric Indications and Dosage-->
 <!--FDA-Labeled Indications and Dosage (Pediatric)-->
-|fdaLIADPed======Condition1=====
+|fdaLIADPed======Conjunctivitis, Ocular irritation=====
+=====Nasal congestion=====
 * Dosing Information
-:* Dosage
+:*For RHINITIS, the usual dose of oxymetazoline in children 2 to 5 years old is 2 to 3 drops of a 0.025% solution in each nostril twice a day for up to 3 days. Drops are preferred to spray dosage forms since dosage can be more easily controlled with the former.
+:*Use should be limited to less than 5 days to minimize occurrence of rebound congestion.
-=====Condition2=====
-There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 <!--Off-Label Use and Dosage (Pediatric)-->
 <!--Guideline-Supported Use (Pediatric)-->
-|offLabelPedGuideSupport======Condition1=====
+|offLabelPedGuideSupport=* There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-* Developed by:
-* Class of Recommendation:
-* Strength of Evidence:
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 <!--Non–Guideline-Supported Use (Pediatric)-->
-|offLabelPedNoGuideSupport======Condition1=====
+|offLabelPedNoGuideSupport=* There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 <!--Contraindications-->
-|contraindications=* Condition1
+|contraindications=
 <!--Warnings-->
-|warnings=* Description
+|warnings=*Ask a doctor before use if you have
-====Precautions====
+:*heart disease
+:*high blood pressure
+:*diabetes
+:*thyroid disease
+:*trouble urinating due to an enlarged prostate gland
-* Description
+*When using this product
-<!--Adverse Reactions-->
+:*do not use more than directed
+:*do not use for more than 3 days. Use only as directed. Frequent or prolonged use may cause nasal congestion to recur or worsen.
+:*temporary discomfort such as burning, stinging, sneezing or an increase in nasal discharge may occur
+:*use of this container by more than one person may spread infection
-<!--Clinical Trials Experience-->
+*Stop use and ask a doctor if
-|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
-=====Body as a Whole=====
+:*symptoms persist
+*If pregnant or breast-feeding,
+:*ask a health professional before use.
+*Keep out of reach of children.
-=====Cardiovascular=====
+:*If swallowed, get medical help or contact a Poison Control Center right away. (1-800-222-1222)
-=====Digestive=====
-=====Endocrine=====
-=====Hematologic and Lymphatic=====
-=====Metabolic and Nutritional=====
-=====Musculoskeletal=====
-=====Neurologic=====
-=====Respiratory=====
-=====Skin and Hypersensitivy Reactions=====
-=====Special Senses=====
-=====Urogenital=====
-=====Miscellaneous=====
+<!--Adverse Reactions-->
+<!--Clinical Trials Experience-->
+|clinicalTrials=* There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 <!--Postmarketing Experience-->
 |postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
-=====Body as a Whole=====
-=====Cardiovascular=====
-=====Digestive=====
-=====Endocrine=====
-=====Hematologic and Lymphatic=====
-=====Metabolic and Nutritional=====
-=====Musculoskeletal=====
-=====Neurologic=====
-=====Respiratory=====
-=====Skin and Hypersensitivy Reactions=====
-=====Special Senses=====
-=====Urogenital=====
-=====Miscellaneous=====
 <!--Drug Interactions-->
-|drugInteractions=* Drug
+|drugInteractions=
-:* Description
 <!--Use in Specific Populations-->
-|FDAPregCat=
 |useInPregnancyFDA=* '''Pregnancy Category'''
 |useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
-|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
+|useInLaborDelivery=* There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
-|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
+|useInNursing=* There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
-|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
+|useInPed=* There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
-|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
+|useInGeri=* There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
-|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
+|useInGender=* There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
-|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
+|useInRace=* There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
-|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
+|useInRenalImpair=* There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
-|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
+|useInHepaticImpair=* There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
-|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
+|useInReproPotential=* There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
-|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
+|useInImmunocomp=* There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 <!--Administration and Monitoring-->
-|administration=* Oral
+|administration=*
 * Intravenous
-|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
+|monitoring=* There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
-* Description
 <!--IV Compatibility-->
-|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
+|IVCompat=* There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 <!--Overdosage-->
-|overdose====Acute Overdose===
+|overdose=* There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
-====Signs and Symptoms====
-* Description
-====Management====
-* Description
-===Chronic Overdose===
-There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 <!--Pharmacology-->
 <!--Drug box 2-->
-|drugBox=<!--Mechanism of Action-->
+|drugBox=[[File:Oxymetazoline wiki.png|600px|thumbnail|left]]
+{{clear}}
 |mechAction=*
@@ Line 305: / Line 145: @@
 <!--Pharmacodynamics-->
-|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
+|PD=* There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 <!--Pharmacokinetics-->
-|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
+|PK=* There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 <!--Nonclinical Toxicology-->
-|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
+|nonClinToxic=* There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 <!--Clinical Studies-->
-|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
+|clinicalStudies=* There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
 <!--How Supplied-->
 |howSupplied=*
-|storage=
+|storage=* store at 20°-25°C (68°-77°F)
-|packLabel=
+*retain carton for future reference on full labeling
-<!--Patient Counseling Information-->
+|packLabel=[[File:Oxymetazoline pdp.png|600px|thumbnail|left]]
-|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
+{{clear}}
-<!--Precautions with Alcohol-->
+[[File:Oxymetazoline label.png|600px|thumbnail|left]]
-|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
+{{clear}}
+|fdaPatientInfo=*adults and children 6 to under 12 years of age (with adult supervision): 2 or 3 sprays in each nostril not more often than every 10 to 12 hours. Do not exceed 2 doses in any 24-hour period.
+*children under 6 years of age: ask a doctor
-<!--Brand Names-->
+*To spray, squeeze bottle quickly and firmly. Do not tilt head backward while spraying. Wipe nozzle clean after use. Replace cap tightly to maintain child resistance.
-|brandNames=* ®<ref>{{Cite web | title =  | url =  }}</ref>
+|alcohol=Alcohol-Oxymetazoline interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
+|brandNames=Afrin,
+-Way Long Lasting,
+Neo-Synephrine 12 Hour,
+Vicks Sinex 12 Hour,
+Visine L.R.,
+Nasacon,
+Sinarest Nasal,
+Duramist Plus.
 <!--Look-Alike Drug Names-->

Oxymetazoline: Difference between revisions

Latest revision as of 19:28, 23 December 2014

Disclaimer

Overview

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Conjunctivitis, Ocular irritation

Nasal congestion

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Non–Guideline-Supported Use

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Conjunctivitis, Ocular irritation

Nasal congestion

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Non–Guideline-Supported Use

Contraindications

Warnings

Adverse Reactions

Clinical Trials Experience

Postmarketing Experience

Drug Interactions

Use in Specific Populations

Pregnancy

Labor and Delivery

Nursing Mothers

Pediatric Use

Geriatic Use

Gender

Race

Renal Impairment

Hepatic Impairment

Females of Reproductive Potential and Males

Immunocompromised Patients

Administration and Monitoring

Administration

Monitoring

IV Compatibility

Overdosage

Pharmacology

Mechanism of Action

Structure

Pharmacodynamics

Pharmacokinetics

Nonclinical Toxicology

Clinical Studies

How Supplied

Storage

Images

Drug Images

Package and Label Display Panel

Patient Counseling Information

Precautions with Alcohol

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

Navigation menu

Search